Research programme: HDL modulators - AbbVie

Drug Profile

Research programme: HDL modulators - AbbVie

Alternative Names: HDL modulators research programme - Abbott; KH01500; KH01501; KH01502

Latest Information Update: 17 Oct 2007

Price : $50

At a glance

  • Originator Kos Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lipid metabolism disorders

Most Recent Events

  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
  • 23 Aug 2005 Preclinical trials in Lipid metabolism disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top